A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer By Ogkologos - November 21, 2025 77 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TRADE study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Tisagenlecleucel Is Safe and Effective in Pretreated Patients with Relapsed/Refractory Follicular... December 21, 2021 Addressing Racial Disparities in Cancer Care: “Your Stories” Podcast May 12, 2022 Longest Follow-Up of CAR T-Cell Therapy in Mantle Cell Lymphoma Points... June 14, 2022 Foodie Fridays: Watermelon Salad August 27, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Dostarlimab Long-Term Follow-Up Confirms Pembrolizumab and Pembrolizumab-Chemotherapy as Effective First-Line Treatment Options... Keeping progress in oncology on the agenda: ESMO honours recipients of... ESMO Gynaecological Cancers Congress 2024, 20-22 June, Florence, Italy
